Bivalirudin (Angiox®) for the treatment of adult patients with acute coronary syndromes planned for urgent or early intervention
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000409
English
Authors' recommendations:
Bivalirudin (Angiox®) (administered with aspirin and clopidogrel) is recommended as an option within NHS Wales for the treatment of adult patients with acute coronary syndromes (unstable angina/non-ST segment elevation myocardial infarction [UA/NSTEMI]) planned for urgent or early intervention.
AWMSG is of the opinion that bivalirudin (Angiox®) is not suitable for shared care within NHS Wales.
Bivalirudin (Angiox®) should only be considered as an option where both a glycoprotein IIb/IIIa inhibitor (GPI) plus heparin would be used as an alternative.
Bivalirudin (Angiox®) should not be used as an alternative where heparin would be used alone.
AWMSG is of the view that the main place in therapy for bivalirudin (Angiox®) is where there is a high risk of bleeding.
Details
Project Status:
Completed
Year Published:
2009
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=124166&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Antithrombins
- Hirudins
- Peptide Fragments
- Recombinant Proteins
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.